LP
EVOK

LMR Partners’s Evoke Pharma EVOK Stock Holding History

LMR Partners’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-166
Closed -$131K – 390
2014
Q3 		$131K Hold
166
– – 0.01% 273
2014
Q2 		$187K Hold
166
– – 0.02% 404
2014
Q1 		$199K Buy
+166
New +$237K 0.03% 227

Other funds holding EVOK

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LMR Partners's EVOK Position: Q4 2014 in Review

LMR Partners sold out of Evoke Pharma (EVOK) in Q4 2014, closing a stake of 166 shares — an estimated $131K sold.

LMR Partners first reported a position in EVOK in Q1 2014 and held it in 3 quarters. The position peaked at $199K in Q1 2014. 11 funds tracked by Wall St. Rank hold EVOK as of Q4 2014.

  • LMR Partners reported no remaining Evoke Pharma position as of Q4 2014 after selling out during the quarter.
  • LMR Partners sold 166 Evoke Pharma shares in Q4 2014, an estimated $131K.
  • LMR Partners first reported a position in Evoke Pharma in Q1 2014 and held it in 3 quarters.
  • LMR Partners's Evoke Pharma position peaked at $199K in Q1 2014.
  • 11 funds tracked by Wall St. Rank held Evoke Pharma as of Q4 2014.

Based on LMR Partners's 13F filing for Q4 2014, filed 20 Jan 2015.